

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5674908

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ROBERT GOODENOW	07/10/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SYNDAX PHARMACEUTICALS, INC.
<b>Street Address:</b>	35 GATEHOUSE DRIVE
<b>Internal Address:</b>	BUILDING D, FLOOR 3
<b>City:</b>	WALTHAM
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02451
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15559402
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	212-479-6656
<b>Email:</b>	zippatentdocketingmailbox@cooley.com
<b>Correspondent Name:</b>	COOLEY LLP, ATTN: PATENT GROUP
<b>Address Line 1:</b>	1299 PENNSYLVANIA AVENUE, NW
<b>Address Line 2:</b>	SUITE 700
<b>Address Line 4:</b>	WASHINGTON, D.C. 20004
<b>ATTORNEY DOCKET NUMBER:</b>	SYND-005N01US 327830-2187
<b>NAME OF SUBMITTER:</b>	ERIC A. OWENS
<b>SIGNATURE:</b>	/Eric A. Owens/
<b>DATE SIGNED:</b>	08/19/2019
This document serves as an Oath/Declaration (37 CFR 1.63).	
<b>Total Attachments: 12</b>	
source=SYND-005N01US_Assignment_Goodenow#page1.tif	
source=SYND-005N01US_Assignment_Goodenow#page2.tif	
source=SYND-005N01US_Assignment_Goodenow#page3.tif	

source=SYND-005N01US\_Assignment\_Goodenow#page4.tif  
source=SYND-005N01US\_Assignment\_Goodenow#page5.tif  
source=SYND-005N01US\_Assignment\_Goodenow#page6.tif  
source=SYND-005N01US\_Assignment\_Goodenow#page7.tif  
source=SYND-005N01US\_Assignment\_Goodenow#page8.tif  
source=SYND-005N01US\_Assignment\_Goodenow#page9.tif  
source=SYND-005N01US\_Assignment\_Goodenow#page10.tif  
source=SYND-005N01US\_Assignment\_Goodenow#page11.tif  
source=SYND-005N01US\_Assignment\_Goodenow#page12.tif

**Syndax Pharmaceuticals, Inc.**

**ASSIGNMENT OF DEVELOPMENTS,  
NON-DISCLOSURE, NON-COMPETITION,  
AND NON-SOLICITATION AGREEMENT**

RECITALS

A. Syndax Pharmaceuticals, Inc. (the "Company") is involved in an extremely competitive industry in which confidentiality of its proprietary information is a valuable corporate asset.

B. The Company's Confidential Information (defined herein) is vital to the success of the Company's business and have been or will be developed or attained by great efforts and expense to the Company.

C. I acknowledge that as of the date of this Agreement and continuing thereafter, I will be provided by the Company with Confidential Information, including trade secrets, concerning the Company and its customers and I recognize the importance of protecting the Company's rights in and to such Confidential Information.

D. The Company's competitive position in the line of business in which it is engaged depends in part upon its ability to safeguard Confidential Information.

E. The Confidential Information being provided to me (pursuant to this Agreement) is necessary for the performance of my duties and could damage the Company or third parties if such Confidential Information were made known to any entity or person engaged in business activities that are in competition with the Company. I acknowledge that without the Company's provision of such Confidential Information I would not be able to accomplish my job duties.

F. The Company will not provide, or will not agree to continue to provide, me with this Confidential Information unless I provide the necessary assurances and commitments to protect this information and the Company's business interests as more fully set forth herein.

G. This Agreement was made available to me prior to the date hereof so as to provide me with an adequate amount of time in which to read the entire Agreement and review its provisions with my counsel and advisors.

H. I understand the meaning and effect of the terms of this Agreement, and due to the extremely competitive nature of the business in which Syndax Pharmaceuticals, Inc. is engaged, I agree that the restrictions contained herein are reasonable and necessary.

NOW, THEREFORE, in consideration of the covenants herein, my employment or continued employment with the Company, and for other good and valuable consideration, I hereby covenant and agree with the Company as follows:

**ARTICLE I**  
Definitions

1.1 Company: The term "Company" shall mean Syndax Pharmaceuticals, Inc. and any parent, subsidiary, affiliate, successor or assign of Syndax Pharmaceuticals, Inc. for which I work or from which I, as an employee, obtained or could have obtained Confidential Information and/or benefited from the business relationships involving Syndax Pharmaceuticals, Inc.

1.2 Confidential Information: The term "Confidential Information" shall mean any trade secret, proprietary or confidential information concerning the organization, personnel, business, finances, products, research and development initiatives, preclinical or clinical trials, or contractual transactions or obligations of the Company, or of any third party which the Company is under an obligation to keep confidential, and that is maintained by the Company as confidential. Such Confidential Information shall include, but is not limited to, trade secrets, proprietary or confidential information respecting existing and future products and services, designs, methods, formulas, drafts of publications, research, know-how, preclinical or clinical trial results, techniques, systems, databases, processes, software programs or code, developments or experimental work, works of authorship, customer lists and/or customer information, business plans, marketing plans, financial information, sales techniques, projects, correspondence with governmental or administrative bodies, the Company's salary and/or pay rates, other Company personnel information, and all other Company plans and proposals.

1.3 Developments: The term "Developments" shall mean any invention, modification, discovery, design, development, improvement, process, software program, work of authorship, documentation, formula, data, technique, know-how, trade secret or intellectual property right whatsoever or any interest therein (whether or not patentable or registrable under copyright, trademark or similar statutes).

**ARTICLE II**  
Disclosure of Developments

2.1 I agree that I will forthwith communicate in writing to the Board of Directors of the Company, or such officer or individual as the Board of Directors of the Company may from time to time designate, a full and complete disclosure of any and all Developments, research and other information, discoveries and improvements made, developed, conceived and/or reduced to practice by me, alone, or jointly with others (i) while in the employ of the Company and (ii) during a one (1) year period following the termination of my employment or other association with the Company if such Developments, research, discoveries or improvements relate to the business of the Company.

2.2 The business of the Company includes any technical or business interest that has been worked on by the Company in the past, or in which there is work in progress at the Company during the period of my employment with the Company. The business interests of the Company include Company operations or activities in the planning stages. I understand that this disclosure of Developments and the following assignment of Developments does not cover any

of my patents or patents applications that are filed or based exclusively on inventions made by me before my employment with the Company.

**ARTICLE III**  
Assignment of Developments

3.1 If at any time or times during my employment or other association with the Company, I shall (either alone or with others) make, conceive, create, discover, invent or reduce to practice any Development that (i) relates to the business of the Company or any customer of or supplier to the Company or any of the products or services being developed, manufactured or sold by the Company or which may be used in relation therewith; or (ii) results from tasks assigned to me by the Company; or (iii) results from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company, then all such Developments and the benefits thereof are and shall immediately become the sole and absolute property of the Company and its assigns, as works made for hire or otherwise. I shall promptly disclose to the Company (or any persons designated by it) each such Development. I hereby assign all rights (including, but not limited to, rights to inventions, patentable subject matter, copyrights and trademarks) I may have or may acquire in the Developments and all benefits and/or rights resulting therefrom to the Company and its assigns without further compensation and shall communicate, without cost or delay, and without disclosing to others the same, all available information relating thereto (with all necessary plans and models) to the Company.

3.2 I will assist, upon request, in locating writings and other physical evidence of the making of my Developments and provide unrecorded information relating to them, and give testimony in any proceeding in which any of my Developments or any application or patent directed thereto may be involved, provided that if I am no longer employed by the Company, reasonable compensation shall be paid for such services. Notwithstanding the foregoing, no obligation is imposed on the Company to remunerate at a higher rate for the giving of testimony than the rate established by law for the compensation of witnesses in the court or tribunal where the testimony is taken. To the extent feasible, the Company will use its best efforts to request such assistance at times and places as will least interfere with any other employment of mine.

3.3 I will promptly disclose to the Company all material which I produce, compose or write, individually or in collaboration with others, which arises out of work delegated to me by the Company. I agree that all such material constitutes a work for hire, and at the expense of the Company, I will assign to the Company all my interest in such copyrightable material and will sign all papers and do all other acts necessary to assist the Company to obtain copyrights on such material in any and all countries.

3.4 Any Development relating to the Company's business made by me within one (1) year following the termination of my employment (and which is required to be disclosed in accordance with Section 2.1 above) shall be presumed to be owned by the Company.

3.5 I represent that the Developments identified in the Appendix attached hereto, if any, comprise all the Developments that I have made or conceived prior to my employment by the Company, which Developments are excluded from this Agreement. I understand that it is

only necessary to list the title of such Developments and the purpose thereof, but not details of the Development itself. IF THERE ARE ANY SUCH DEVELOPMENTS TO BE EXCLUDED, THE UNDERSIGNED SHOULD INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS. \_\_\_\_\_.

**ARTICLE IV**  
Non-Disclosure

4.1 I agree that I will not, at any time, whether during or after the termination of my employment, without first obtaining the written approval of the Board of Directors of the Company, or of such officer or individual as the Board of Directors of the Company may from time to time designate, divulge or disclose to any person or entity outside of the Company, whether by private communications or by public address or publication, or otherwise, any Confidential Information, except to the extent that such disclosure is necessary to perform my duties and fulfill my responsibilities as an employee of the Company. All original and copies of any Confidential Information or other written materials relating to the business of the Company, however and whenever produced, shall be the sole property of the Company and shall be surrendered to the Company upon termination of my employment.

4.2 I shall keep confidential all matters entrusted to me and shall not use or attempt to use any Confidential Information, including confidential information related to third parties which the Company is obligated to maintain as confidential, except as may be required in the ordinary course of performing my duties as an employee of the Company, nor shall I use any Confidential Information in any manner which may injure or cause loss or may be calculated to injure or cause loss to the Company, whether directly or indirectly.

**ARTICLE V**  
Non-Competition

5.1 I agree that while in the employ of the Company and for six months thereafter (the "Restriction Term"), regardless of the reasons for my termination, I shall not, directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer, lender or stockholder of any entity (a) accept employment or establish any other relationship with any business within the United States that is in competition with the products or services created, developed or under development, manufactured or planning to be manufactured, marketed or planning to be marketed, distributed or planning to be distributed, sold or planning to be sold, by the Company at the time of my termination (collectively, the "Products And Services"), or (b) engage in any business or activity within the United States that is in competition with the Products And Services, provided, however, that the record or beneficial ownership of five (5) percent or less of the outstanding publicly traded capital stock of any entity shall not be deemed, in and of itself, to be in violation of this Section. Notwithstanding the above, for Company employees classified as sales persons assigned to a distinct geographic area and for employees classified as service providers with an assigned geographic area, the geographic scope of their Restriction Term shall be limited to the geographic area to which assigned as an employee of Company.

**ARTICLE VI**  
Non-Solicitation Of Employees

6.1 I agree that during the Restriction Term, regardless of the reasons for my termination, I will not directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer, lender or stockholder of any entity, recruit or solicit for hire any Company employee, agent, representative or consultant, or any such person who has terminated his/her relationship with the Company within six months of my departure from the Company.

**ARTICLE VII**  
Company Property

7.1 I agree that during my employment I shall not make, use or permit to be used any Company Property otherwise than for the benefit of the Company. The term "Company Property" shall include all notes, memoranda, reports, lists, records, drawings, sketches, rolodexes, specifications, software programs, software code, data, computers, cellular telephones, pagers, palm pilots and their equivalents, credit and/or calling cards, keys, access cards, documentation or other materials of any nature and in any form, whether written, printed, electronic or in digital format or otherwise, relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs, and any other Company property in my possession, custody or control. I further agree that I shall not, after the termination of my employment, use or permit others to use any such Company Property. I acknowledge and agree that all Company Property shall be and remain the sole and exclusive property of the Company. Immediately upon the termination of my employment I shall deliver all Company Property in my possession, and all copies thereof, to the Company.

**ARTICLE VIII**  
Employment At-Will

8.1 I understand that this Agreement does not alter my status as an "at-will" employee of the Company. Accordingly, I understand that either the Company or I may terminate my employment at any time, for any or no reason, with or without prior notice.

**ARTICLE IX**  
Best Efforts

9.1 During the period of my employment by the Company, I shall devote my full time and best efforts to the Company's business, and I shall neither pursue any business opportunity outside the Company nor take any position with any organization other than the Company without the approval of the Company's Chief Executive Officer, provided, however, that I may participate in professional, civic, social and/or charitable activities that do not adversely affect my ability to carry out my responsibilities to the Company.

**ARTICLE X**  
**General Provisions**

10.1 I agree that this Agreement shall be binding upon me irrespective of the duration of my employment or other association with the Company, the reasons for the cessation of my employment or other association with the Company, or the amount of my wages and/or salary.

10.2 This Agreement sets forth the complete, sole and entire agreement between the parties with respect to the subject matter herein and supersedes any and all other agreements, negotiations, discussions, proposals, or understandings, whether oral or written, previously entered into, discussed or considered by the parties. No modification or variation to this Agreement shall be deemed valid unless in writing and signed by the Company.

10.3 This Agreement shall be binding upon my heirs, executors, administrators and legal representatives, and shall inure to the benefit of the successors and assigns of the Company. I shall not assign this Agreement.

10.4 I represent and warrant to the Company that I am not under any obligations to any person, firm, corporation, or other business entity, and have no other interest which is inconsistent or in conflict with this Agreement, or which would prevent, limit or impair, in any way, the performance by me of any of the covenants hereunder or my duties in my employment with the Company. I have not entered into, and shall not enter into, any agreement either oral or written in conflict herewith.

10.5 I represent that my employment with the Company and my performance of all of the terms of this Agreement do not and will not breach any agreement to keep in confidence, proprietary information acquired by me in confidence or trust prior to my employment by the Company, nor will it violate any non-solicitation and/or non-competition agreements entered into prior to my employment with the Company. I have not entered into, and I shall not enter into, any agreement, either written or oral, in conflict herewith.

10.6 I agree that any breach of this Agreement by me will cause irreparable damage to the Company and in the event of such breach the Company shall have, in addition to any and all remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violations of my obligations hereunder.

10.7 Any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach of such provision or any other provision hereof. In addition, any amendment to or modification of this Agreement or any waiver of any provision hereof must be in writing and signed by the Company.

10.8 I agree that each provision and the subparts of each provision herein shall be treated as a separate and independent clause, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of the Agreement. Moreover, if one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise, so as to be unenforceable by law, such provision or provisions shall be construed by the appropriate judicial body by limiting or reducing it or them, so as to be enforceable to the maximum extent compatible with the



applicable law as it shall then appear. I hereby further agree that the language of all parts of this agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for or against either of the parties.

10.9 The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.

10.10 I acknowledge and agree that the Company conducts business globally and that the Company has an interest in the uniform interpretation and enforcement of its Employment Agreements. Accordingly, I acknowledge and agree that this Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts and shall in all respects be interpreted, enforced and governed under the internal and domestic laws of such state, without giving effect to the principles of conflicts of laws of such state. I further agree that any claims or legal actions by one party against the other arising out of the relationship between the parties contemplated herein (whether or not arising under this Agreement) shall be governed by the laws of the Commonwealth of Massachusetts and shall be commenced and maintained in any state or federal court located in such state, and I hereby submit to the jurisdiction and venue of any such court.

I REPRESENT THAT I HAVE READ THE FOREGOING AGREEMENT, THAT I FULLY UNDERSTAND THE TERMS AND CONDITIONS OF SUCH AGREEMENT AND THAT I AM KNOWINGLY AND VOLUNTARILY ENTERING INTO THIS AGREEMENT. NO PROMISES OR REPRESENTATIONS (OTHER THAN THE REPRESENTATIONS SET FORTH HEREIN) HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT.

Name:

Digitally signed by Bob Goodenow  
DN: c=US, st=Massachusetts,  
l=Waltham, o=Syndax  
Pharmaceuticals, cn=Bob Goodenow,  
email=bgoodenow@syndax.com  
Date: 2013.07.09 14:42:32 -07'00'


Employee:



Date: \_\_\_\_\_

Signature

Witness:



Date: 7/10/13


## APPENDIX – TITLE/PURPOSE OF DEVELOPMENTS

The following is a complete list of all Developments and the purpose of those Developments:

\_\_\_\_\_ No Developments  
XX See Below

Developments and purpose (Please list any patents by patent number and any patents pending):

**Exhibit A** provides a listing of pending patent applications.



Digitally signed by Bob  
Goodenow  
DN: c=US, st=Massachusetts,  
l=Waltham, o=Syndax  
Pharmaceuticals, cn=Bob  
Goodenow,  
email=bgoodenow@syndax.com  
Date: 2013.07.12 12:19:38 -07'00'

\_\_\_\_\_  
Print Name

**Exhibit A**

Type	App Number	Filing Date	Title	Inventor(s)
ORD	US2008/70935	23-Jul-2008	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	60/951,422	23-Jul-2007	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PCT	12/670,390	02-Jul-2010	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2008/70828	23-Jul-2008	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	60/951,430	23-Jul-2007	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2008/70827	23-Jul-2008	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	60/951,435	23-Jul-2007	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2008/70884	23-Jul-2008	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	60/951,433	23-Jul-2007	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PCT	12/670,385	07-Jul-2010	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2008/79298	09-Oct-2008	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	60/978,955	10-Oct-2007	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	60/983,671	30-Oct-2007	NOVEL COMPOUNDS AND METHODS OF USING THEM	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2008/84009	19-Nov-2008	ADMINISTRATION OF AN INHIBITOR OF HDAC	BURK, KONRAD; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	60/989,082	19-Nov-2007	ADMINISTRATION OF AN INHIBITOR OF HDAC	BURK, KONRAD; ORDENTLICH, PETER; GOODENOW, ROBERT
PCT	12/743,557	09-Aug-2010	ADMINISTRATION OF AN INHIBITOR OF HDAC	BURK, KONRAD; ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2008/81625	29-Oct-2008	ADMINISTRATION OF AN INHIBITOR OF HDAC AND AN MTOR INHIBITOR	BURK, KONRAD; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	60/983,892	30-Oct-2007	ADMINISTRATION OF AN INHIBITOR OF HDAC AND AN MTOR INHIBITOR	BURK, KONRAD; ORDENTLICH, PETER; GOODENOW, ROBERT

Type	App Number	Filing Date	Title	Inventor(s)
ORD	12/260,883	29-Oct-2008	ADMINISTRATION OF AN INHIBITOR OF HDAC AND AN mTOR INHIBITOR	BURK, KONRAD; ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2009/39529	03-Apr-2009	ADMINISTRATION OF AN INHIBITOR OF HDAC AND AN HMT INHIBITOR	ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	61/043,055	07-Apr-2008	ADMINISTRATION OF AN INHIBITOR OF HDAC AND AN HMT INHIBITOR	ORDENTLICH, PETER; GOODENOW, ROBERT
PCT	2,725,390	07-Apr-2009	ADMINISTRATION OF AN INHIBITOR OF HDAC, AN INHIBITOR OF HER-2, AND A SELECTIVE ESTROGEN RECEPTOR MODULATOR	ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2009/39824	07-Apr-2009	ADMINISTRATION OF AN INHIBITOR OF HDAC, AN INHIBITOR OF HER-2, AND A SELECTIVE ESTROGEN RECEPTOR MODULATOR	ORDENTLICH, PETER; GOODENOW, ROBERT; LIU, BOLIN; HUANG, XIAOPING
PRO	61/043,342	08-Apr-2008	ADMINISTRATION OF AN INHIBITOR OF HDAC, AN INHIBITOR OF HER-2, AND A SELECTIVE ESTROGEN RECEPTOR MODULATOR	ORDENTLICH, PETER; GOODENOW, ROBERT
PCT	12/936,887	11-Apr-2011	ADMINISTRATION OF AN INHIBITOR OF HDAC, AN INHIBITOR OF HER-2, AND A SELECTIVE ESTROGEN RECEPTOR MODULATOR	ORDENTLICH, PETER; GOODENOW, ROBERT; LIU, BOLIN; HUANG, XIAOPING
PRO	61/140,036	22-Dec-2008	ADMINISTRATION OF HDAC INHIBITOR AND AN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITOR	ORDENTLICH, PETER; GOODENOW, ROBERT
ORD	US2011/038961	02-Jun-2011	PRODRUGS OF AZACITIDINE 5'-PHOSPHATE	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	61/351,789	04-Jun-2010	PRODRUGS OF AZACITIDINE 5'-PHOSPHATE	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	61/351,797	04-Jun-2010	PRODRUGS OF AZACITIDINE 5'-PHOSPHATE	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	61/492,275	01-Jun-2011	PRODRUGS OF AZACITIDINE 5'-PHOSPHATE	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT
PRO	61/476,227	15-Apr-2011	SOLID STATE FORMS OF N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YL)-METHOXYCARBONYLAMINO]METHYL]-BENZAMIDE	GOODENOW, ROBERT; EDGAR, MARK
PRO	61/482,573	04-May-2011	PHARMACOKINETICS OF SOLID STATE FORMS OF N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YL)-METHOXYCARBONYLAMINO]METHYL]-BENZAMIDE	GOODENOW, ROBERT
PCT	201201474	31-Aug-2012	METHODS FOR THE TREATMENT OF BREAST CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER

Type	App Number	Filing Date	Title	Inventor(s)
PCT		31-Aug-2012	METHODS FOR THE TREATMENT OF BREAST CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
ORD	PCT/US2012/053551	31-Aug-2012	METHODS FOR THE TREATMENT OF BREAST CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
PCT	a 2012 13781	31-Aug-2012	METHODS FOR THE TREATMENT OF BREAST CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
PRO	61/530,873	02-Sep-2011	METHODS FOR THE TREATMENT OF BREAST CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
PRO	61/532,534	08-Sep-2011	METHODS FOR THE TREATMENT OF BREAST CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
PRO	61/628,999	12-Nov-2011	CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS	GOODENOW, ROBERT; ORDENTLICH, PETER
PRO	61/568,110	07-Dec-2011	METHODS FOR THE TREATMENT OF BREAST CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
PRO	61/569,135	09-Dec-2011	METHOD FOR THE TREATMENT OF LUNG CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
PRO	61/819,505	03-May-2013	METHOD FOR THE TREATMENT OF CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
ORD	13/708,856	07-Dec-2012	METHOD FOR THE TREATMENT OF LUNG CANCER	GOODENOW, ROBERT; ORDENTLICH, PETER
ORD	PCT/US2012/39685	25-May-2012	PRODRUGS OF AZACITIDINE 5-DIPHOSPHATE	KEANA, JOHN F.W.; ORDENTLICH, PETER; GOODENOW, ROBERT